News >

Ramucirumab Misses OS Endpoint in Phase III Urothelial Carcinoma Trial

Jason M. Broderick @jasoncology
Published: Monday, Apr 23, 2018

Levi Garraway, MD, PhD
Levi Garraway, MD, PhD
Combining ramucirumab (Cyramza) with docetaxel in patients with locally advanced or unresectable metastatic urothelial carcinoma who progressed on platinum-based chemotherapy led to a positive trend, but not a statistically significant improvement, in overall survival (OS), according to Eli Lilly and Company, the manufacturer of the VEGFR2 inhibitor.  

Treatment was discontinued, primarily due to progressive disease, in 209 patients on ramucirumab/docetaxel and 229 patients on placebo/docetaxel. Forty-nine patients in the combination arm remain on treatment compared with 36 in the docetaxel monotherapy arm.
Petrylak D Chi KN, Drakaki A, et al. RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma. Presented at 2017 ESMO Congress; September 8-12, 2017; Madrid, Spain. Abstract LBA4_PR.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: New York Advanced Practice CollaborativeNov 15, 20191.25
Medical Crossfire®: Treating MS in the Modern Era: Right Patient, Right Treatment, Right TimeApr 20, 20201.5
Publication Bottom Border
Border Publication
x